Canadian Lyme Disease Foundation [ CanLyme ]

Lyme disease test

blue disease | blue ear disease | blue-ear disease of pigs | mysterious pig disease | mysterious swine disease | mystery pig disease | new pig disease | porcine epidemical abortion | porcine reproductive and respiratory syndrome | purple ears disease | MSD [Abbr.] | PRRS [Abbr.]

axophthalmic goitre | basedowified goiter | Basedow's disease | exophthalmic goiter | exophthalmica | Flajani's disease | Graves disease | hyperthyreosis | hyperthyroidism | Parry's disease | thyroid cachexia | thyroiditis | thyrotoxia | thyrotoxicosis | toxic goiter

trinucleotide repeat disorder | triplet repeat disorder | trinucleotide repeat disease | triplet repeat expansion disorder | trinucleotide-repeat expansion disease | disorder caused by expansion of triplet repeats

swineherd's disease

People used to say, “There isn't Lyme disease in Canada”, or “There isn't Lyme disease in my province”, or “We don't get Lyme disease on Vancouver Island”.

They say a number of things about this disease, including that Canadians will benefit from the establishment of a national standard of care for the treatment of Lyme disease, a coordinated national effort to track the spread of the disease and increased public education and awareness to better prevent and detect instances of Lyme disease in Canada.

(Return tabled) Question No. 223 Ms. Kirsty Duncan: With respect to Lyme disease-carrying ticks and Lyme disease in Canada: (a) what percentage of Lyme disease cases are thought to be reported, (i) what percentage of people who receive treatment for Lyme disease develop post-treatment Lyme disease syndrome, (ii) what percentage of people with untreated Lyme disease infections experience intermittent bouts of arthritis, (iii) what percentage of untreated Lyme disease patients are at risk of developing chronic neurological complaints months to years after infection; (b) based on all epidemiological data collected since Lyme disease became ...[+++] a nationally-reportable disease, what is the most recent data available about Lyme disease cases, broken down (i) by province, (ii) by month, (iii) by symptom, (iv) incidence by age and sex; (c) how does the government define a “Lyme-endemic area”, (i) in what specific areas of Canada are ticks endemic and highly endemic, (ii) what areas of Canada have the highest numbers of human infections; (d) what is Lyme disease’s (i) ranking among vector-borne diseases in Canada, (ii) ranking among nationally notifiable diseases; (e) is it possible to have more than one tick-borne infection, and, if so, (i) are possible co-infections being investigated and tracked, (ii) does one’s chance of having multiple tick-borne infections depend on geographic location, and, if so, what areas are particularly at risk, (iii) what is the rate of co-infection by province; (f) broken down by province, over the last 20 years, how has a warming climate impacted Lyme disease, in particular, (i) how has warming impacted tick distribution by province, (ii) how has warming impacted the distribution of Lyme disease by province; (g) what does the government project will be the effect of climate change on (i) the geographical range of ticks in 2020 and 2050, (ii) the distribution of ticks across Canada, (iii) human Lyme disease infections, (iv) the distribution o ...

(Return tabled) Question No. 8 Ms. Judy Wasylycia-Leis: With respect to the government’s actions to detect, prevent and treat Lyme disease in Canada: (a) by what standard is the accuracy of Lyme disease testing conducted at the National Microbiological Laboratories evaluated; (b) when was the most recent independent evaluation of the proficiency of this testing conducted, by whom and what were the results; (c) what are the current criteria for determining whether a geographical area is deemed to be endemic for Lyme-infected ticks; (d) what is the projected schedule of field study with regard to such endemic areas; (e) with respect to ...[+++] the recommendations of the National Conference on Lyme Disease hosted by the Public Health Agency of Canada (PHAC) in March 2006, (i) have the committees to develop new guidelines on surveillance, clinical and laboratory criteria been formed and, if so, when have they met, (ii) what stakeholder groups have participated in the development of new guidelines, what form has that participation taken, and when did it occur; (f) what is the government's strategy to protect canadians from the increase in incidents of Lyme disease anticipated by PHAC; (g) what is PHAC's strategy to increase (i) physicians' and other health professionals' awareness of the symptoms of Lyme disease, (ii) the canadian public's awareness of the symptoms of Lyme disease; (h) what measures has the PHAC taken in conjunction with provincial health authorities to increase professional and public awareness; (i) what are PHAC's measurable targets for the future increase of awareness and diagnostic accuracy of Lyme disease; (j) does Health Canada recommend the screening of blood for Lyme disease or co-infections such as babesiosis, as done in the United States and, if not, why not; and (k) what research projects into lyme borelia and tick-borne co-infections, their epidemiology, their possible role in the occurence of other diseases, and their treatment are current ...